Posted on

Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets

Lobe Sciences Announces Common Stock to Trade Under the Symbol “LOBEF” in US Markets

Vancouver, British Columbia–(Newsfile Corp. – November 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) (“Lobe” or the “Company“) today announced that its common stock ticker will change from “GTSIF” to “LOBEF” and will commence trading under the symbol “LOBEF” in US markets at the opening of the market on November 15, 2021 and will continue to trade under the ticker symbol “LOBE” on the CSE.

Philip Young, CEO, commented, “The ticker change now reflects the name of the company along with our commitment to investigating and developing treatments using alternative and nontraditional medicines to better brain health.”

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103486

Posted on

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience

Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Krysalis VX Innovations Inc. (“Krysalis”), the Virtual experience (“VX”)-focused company designing the delivery of immersive, headset-free experiences through the KrysalisTM Pod system that will offer treatment options for cognitive, psychological, motor and functional impairments across various clinical health conditions, has appointed a distinguished and future-facing advisory team composed of Alex McDowell, Jon 9, Austin Blaisdell, and the three minds behind sonic engineering company, Resonant Devices, Kent Noonan, Erik Larson and Casey Atteberry.

Krysalis was formed pursuant to a joint venture agreement between Lobe and Virtual Psychedelics Incorporated (“VPI”) announced on April 27, 2021, where Krysalis is owned 50% by Lobe and 50% by VPI.

This advisory group will assist Krysalis through its first iteration of the KrysalisTM Pod. The current leadership team of Krysalis, CEO and social network-transmedia pioneer, Josh Shore; Hollywood director, futurist, and KrysalisTM Pod project lead, Brett Leonard; Professor and Director of Medical Virtual Reality at USC’s Institute for Creative Technologies, Dr. Albert (Skip) Rizzo; and VIP Event Producer, William (Billy) Alfonso (Formula-1, Cirque du Soleil) – are thrilled that the KrysalisTM Pod development will now benefit from representation and expertise of the advisory team that spans across arts, technology, design, academic and industry sectors.

“As a cinematic storyteller, having told cautionary tales of the transformative power of Virtual Reality in my movies, to now be involved in the actual reality of using this technology thanks to our groundbreaking partnership with Lobe Sciences and the incredible advisory group being announced here, is the realization of my greatest hopes for Virtual eXperience (VX) to be a positive force for healing the human spirit,” said Brett Leonard. “The best part is, with the development of the KrysalisTM Pod, no one in these therapeutic environments will have to strap an uncomfortable device on their head.”

Krysalis is committed to further developing systems that deliver virtual experience in tandem with psychedelics for research and clinical therapy, developing VR systems without psychedelics for recreational purposes such as gaming, and is focused on the development of the KrysalisTM Pod. The KrysalisTM Pod is new technology that will harness biometric feedback to make visible the tangible combined effects of virtual reality (“VR”) and psychedelics on biometric activity in real time. With this ability, the implementer (researcher or clinician) will be able to monitor both the psychedelic and the immersive experience such that it will be uniquely tailored to individual responses, and thus moderated to maximize the desired effect and therapeutic outcomes.

“I am impressed with the depth and capabilities of the Advisory team assembled by Krysalis management,” said Philip Young, CEO Lobe Sciences Ltd. “We have confidence that working together they will be able to create an industry leading VX experience that may aid those suffering from depression, PTSD and other mental health issues.”

This advisory team will be pivotal in defining aesthetic and pragmatic attributes of Krysalis VX’s treatment-oriented technology. The advisory team consists of:

Alex McDowell Award-winning designer, storyteller, and founder and creative director of Experimental Design where McDowell and his team design immersive story worlds for industries and institutions. He is simultaneously a professor of practice at USC School of Cinema, where he directs the World Building Media Lab and World Building Institute and teaches world building as a media and platform-agnostic narrative design practice. Alex is also known as one of the top Hollywood production designers, having worked on some of the biggest visionary Hollywood blockbusters such as Steven Spielberg’s “Minority Report”.

Jon 9 is a Creative Technologist who handles large-scale digital display projects, streaming immersive spaces, content creation and post-production management for complex systems. He’s realized massive projects including Cirque du Soleil: Beatles LOVE at The Mirage Las Vegas, installations with Disney, and many others with icons and mega-brands from Michael Jackson and Aretha Franklin to Audi and The Emmy Awards. His expertise is rooted in developing experiential media spaces that require new techniques and technologies.

Austin Blaisdellis a design strategist and art director who uses 3D printing, Virtual Reality, and the entire digital universe to project visions spanning all arts-related genres. His spatial design, visual direction, and design solutions may be experienced internationally, at exhibitions from Los Angeles to New York to Paris.

Kent Noonan is an Electronic Engineer whose expertise spans all areas of design and manufacturing, lasers and optics, high performance electronics and tough industrial devices, alternative healing with light and electromagnetic frequencies, free energy devices and alternate fuels, plasma, cymatics, and structured water research.

Erik Larsonis an inventor, design engineer, musician, instrument builder, and entrepreneur. His professional specialties include business development, business management, patent and IP development, product development, technology integration, systems design, and team building.

Casey Atteberry is a mathematician striving to translate material in an approachable way to people of all ages and levels of interest. He has been an independent math and acoustical physics research scientist for nearly two decades, studying concepts from quantum computation to cymatics and fluid dynamics.

* * *

About Krysalis VX Innovations Inc.

Krysalis VX Innovations Inc. exists to design sophisticated, immersive treatments for psychological, cognitive and physical challenges. The KrysalisTM Pod will be designed to be powered by a custom tech stack incorporating advanced display technology and state-of-the-art bio-monitoring with the goal of improving psychedelic therapy by optimizing set, setting and the overall experience for clinical and other uses. The KrysalisTM Pod will deliver headset-free, virtual experiences that integrate multi-sensory stimulation to create an application that can offer treatment options for cognitive, psychological, motor and functional impairments across a wide range of clinical health conditions.

About Virtual Psychedelics Incorporated (“VPI”)

VPI was formed to pioneer the integration of Psychedelic Therapies with Virtual Experience known as “VX” (Virtual Reality, Augmented Reality & Mixed Reality). Founded by the leading minds in both clinical and entertainment-based Virtual Reality, VPI is dedicated to developing new approaches for the treatment of neurological and psychiatric conditions, and for promoting wellness, alongside the technologies and processes to make them scalable. In addition to medicinal applications, this marriage of ancient and modern technologies has enormous potential for promoting self-understanding and social transformation.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

For press inquiries on Krysalis, please contact Jessie Cohen PR & Consulting:
Jessie Cohen
jessie@jessieiscohen.com
+1 415 623 0150

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, statements related to the development and commercialization of the KrysalisTMPod, including systems, treatments and benefits thereof, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices, including the KrysalisTMPod, produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; Krysalis may be unsuccessful in designing and commercializing the KrysalisTM Pod and/or the risk that the Company may not realize a return on its investment in Krysalis; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences

Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences

Vancouver, British Columbia–(Newsfile Corp. – October 5, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the BioFuture 2021 Conference taking place October 5-6, 2021, and will present virtually at the MoneyShow Virtual Expo taking place October 5-7, 2021

Philip Young, CEO and Director, will have his presentation streamed throughout the conference at the Lobe virtual booth during the BioFuture 2021 Conference and will present at the MoneyShow Virtual Expo at 12:40 P.M. ET on Thursday, October 7, 2021.

The events are accessible using the following links:

BioFuture 2021: https://biofuture.com/biofuture-registration/.
MoneyShow Virtual Expo: https://online.moneyshow.com/2021/october/virtual-expo/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. This does not constitute an offer to sell or a solicitation of offers to buy any securities. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Bring on the fights! 💥

Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD

Lobe Sciences (LOBE) is partnering with the the World Boxing Association (“WBA”) to help boxers manage brain injuries!

The organizations plan to launch a global registry to identify former and current boxers with mild traumatic brain injury (mTBI) and help them manage the side effects, which can often include PTSD. The WBA will also develop best practices for early diagnosis of mTBI that can be used immediately after fights for current boxers.

Injured boxers could potentially be treated with Lobe’s therapeutic regimen, which utilizes the combination of psilocybin and NAC (the pneumonia drug) mentioned in last week’s issue.

PDF of article

Posted on

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Lobe Sciences Announces Data Demonstrating That Its Combination
Therapeutic Candidates are Significantly More Effective Than
Monotherapy in mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD

VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ – Lobe Sciences Ltd. (“Lobe” or the “Company“) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion (“mTBI”) and post-traumatic stress disorder (“PTSD”), using psilocybin plus N-Acetylcysteine (“NAC”). The study is being conducted in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the leadership of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P < 0.000005) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

Philip Young, CEO of Lobe stated, “I am thankful to Dr. Hoffer and his team for their excellent work. This data is validation of our therapeutic hypothesis that the use of these two active therapeutics provides superior efficacy to either placebo or single drug therapy in this model of TBI and PTSD. We believe that these data directly support our IP and will allow us to build on our leadership position in the rapidly evolving psychedelic therapeutics marketplace. Despite the significant shortage of psilocybin in North America the Miami team was able to deliver these data. However, the shortage has impacted the timing of the next planned studies. We have responded to this supply shortage by working to identify a manufacturing company who will supply high purity cGMP psilocybin to the University of Miami so that the remaining studies can be completed.”

Dr. Hoffer stated “These are promising results that suggest that a combination of psilocybin and NAC can work better than either drug administered as a single agent after traumatic brain injury.  We look forward to future work that will help to reaffirm these outcomes and further clarify the role of medical countermeasures in combatting traumatic insults to the brain.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are extremely pleased that the interim data from our preclinical studies validates our therapeutic hypothesis that NAC plus psilocybin would provide superior efficacy over either agent used alone. NAC remains the only compound that has successfully completed a human phase 1 equivalent trial in a population of individuals who had acute mTBI. Dr. Hoffer’s team has made significant in-roads studying psychedelic medicine and NAC specifically as it relates to mTBI and PTSD. Given there are currently no approved medicinal treatments for mTBI and PTSD, we feel this data is supportive of our plans to advance into future human clinical trials which we hope will eventually lead to approved therapeutics for these unmet needs.”

Trials Methodology And Results

Rodent models have been essential for revealing the normal and pathological processes that influence learning and memory. The University of Miami team has extensive experience and expertise in running these and other important models. In a standard model of normal behavior that assess the amount of time that rodents exhibit exploratory activity, rodents who underwent trauma and treated with the combination agents spent significantly more time exploring than they did with single agents or vehicle alone. The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P < 0.000005) than the rodents treated with monotherapy with psilocybin, NAC or placebo.

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines.  The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE NOT REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company; the development of effective delivery methods and commercialization potential of the nasal mist device; research and development using NAC and psilocybin and growth of the business; the timing of and results from the University of Miami pre-clinical study; the ability to access a supply high purity cGMP psilocybin for the Company’s studies; anticipated timing and announcement of initiation of the first human study with Lobe’s patent pending combination therapeutics of psilocybin and NAC (N-Acetylcysteine); statements and expected timing regarding cGMP psilocybin supply and availability; expected advancement into future human clinical trials; statements regarding future approved therapeutics; and the expected timing for the launch of new products and revenue-generating activities, are all forward looking statements that involve risks and uncertainties. Forward-looking statements, by their very nature, require management to make assumptions and are subject to inherent risks and uncertainties, and while management of the Company believes the forward-looking statements contained herein have a reasonable basis, the possibility exists that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate. Material assumptions that underlie the forward-looking statements included in this news release include, without limitation, assumptions regarding: the outcomes of scientific studies showing the efficacy of psychedelic therapies on mTBI and PTSD, increasing acceptance in the medical community and among consumers for psychedelic therapies as an effective treatment modality; the Company having access to sufficient capital needed to support its various objectives, expected synergies from M&A transactions and the timing of future studies, regulatory approvals and our ability to capitalize on business opportunities; the Company having availability and supply of high-purity cGMP psilocybin; and the impact of COVID-19 on our business plans.  Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect.  As a result of the inherent uncertainty of forward-looking statements, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements, whether as a result of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Important risks and uncertainties that could cause actual results to differ materially from the Company’s expectations include without limitation risks relating to: that we may not have the capital needed or will not be able to raise sufficient capital to support our business activities or achieve our anticipated milestones; delays or stoppages in the Company’s business activities resulting from the COVID-19 pandemic; adverse or unexpected findings in scientific research; adverse changes to the regulatory environment in which we operate; regulatory delays or the failure to obtain required regulatory approvals; failure to capitalize on business opportunities and develop revenue-generating activities; contract counterparty risks; key personnel risk; business integration risks; risks inherent to equity and debt markets and their effects on our share price, and such other risks as may be detailed from time to time in the filings made by the Company pursuant to securities regulations, as well as other risks that may presently be unknown to us or which we consider to be immaterial at the time such forward-looking statements are made. As a result of these risks and uncertainties, the Company cannot guarantee that any forward-looking statement will materialize as expected, and the reader is therefore cautioned not to place undue reliance on any forward-looking statements contained in this news release. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, are made only as of the date of this news release and the Company does not intend to update any of the forward-looking statements contained in this news release except as expressly required by applicable securities laws.

SOURCE Lobe Sciences Ltd.

Posted on

Enhancing psilocybin…with a pneumonia drug?

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

A drug that loosens mucus in the lungs could also help treat concussions!?

Lobe Sciences (LOBE) discovered that psilocybin might work better when paired with N-Acetylcysteine (NAC), a drug used to treat Tylenol overdose and respiratory conditions like pneumonia, bronchitis, and asthma.

In rodent models of mild traumatic brain injury (TBI) and PTSD, the combination of psilocybin and NAC performed significantly better than psilocybin, NAC, or a placebo alone.

The company is working on finding a supplier of high purity cGMP psilocybin to continue research and expand on these findings.

PDF of article

Posted on

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Lobe Sciences to Present at the Benzinga Healthcare Small Cap Conference

Vancouver, British Columbia–(Newsfile Corp. – September 27, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the Benzinga Healthcare Small Cap Conference taking place September 29-30, 2021.

Philip Young, CEO and Director will begin his presentation at 10:30 A.M. ET on Wednesday, September 29, 2021.

The event is accessible using the following link: https://www.benzinga.com/events/small-cap/healthcare/september-29-track-1/.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

Posted on

Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference

Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference

Vancouver, British Columbia–(Newsfile Corp. – September 15, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference presented by Maxim Group and hosed by M-Vest taking place Sept. 22, 2021.

The discussion will focus on the topics surrounding Deliver, Manufacturing, & Technology and “What does it take to succeed in Psychedelics beyond drugs and clinics”, beginning at 3:00 P.M. ET on Wednesday, Sept. 22, 2021.

Registration for the event is accessible via https://m-vest.com/events/advances-in-mental-health.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

NEITHER THE CSE, NOR ITS REGULATION SERVICES PROVIDER HAVE  REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

info
Posted on

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Lobe Sciences Provides Corporate Update to Investors and Stakeholders

Vancouver, British Columbia–(Newsfile Corp. – September 13, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to provide the following corporate update by CEO Philip Young, addressed to shareholders, investors and other stakeholders of the Company:

Dear Fellow Shareholders and Psychedelic Medicine Enthusiasts,

We are pleased to say that 2021 has been a busy and transformative year for the Company. During 2021, we have made significant progress on several fronts, and completed our transition to an integrated pharmaceutical development company. We have built the foundation of a drug development company and we are now following a path for the development of therapeutics for which we intend to seek FDA approval in the United States, and similar approvals internationally. Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Our goal is to change that fact. We believe that psychedelic based therapeutics will bring a new era of treatment for many illnesses where current therapies are insufficient or unavailable. As such, we believe the Company is poised to lead the way in developing treatments for mTBI and PTSD, while altering the perception of psychedelic medicine as a treatment modality. Our entire team is dedicated to making a significant impact in this rapidly growing industry as we differentiate ourselves from other psychedelic medicine companies by executing our strategic plans and vision. The following is a brief review of the achievements we have made, laying the foundation for continued progress and milestones, which we believe will position the Company for long-term growth and success.

2021 Business Developments – the building blocks for our future

Our 2021 accomplishments spanned every aspect of our business as we executed our multi-prong strategy and vision for future developments. These accomplishments included: streamlining operations, enhancing our balance sheet, strengthening our intellectual property portfolio, further developing our medical devices, increasing our scientific breadth and reach by forming a world class scientific advisory board and entering into relationships with key organizations that promote mental health and wellness. Key accomplishments include:

Clinical and Scientific Developments and Operations:

Our pre-clinical study involving psilocybin and NAC (N-Acetylcysteine) led by Principal Investigator, Dr. Michael Hoffer of the University of Miami is progressing and in the process of analyzing the data. The Company continued to strengthen its overall product, device and intellectual property (“IP“) portfolio through acquisitions and our development efforts. Other key highlights include:

  • On February 18, 2021 we announced the successful completion and testing of the proof of concept prototype of its proprietary nasal mist device;
  • On April 27, 2021 we announced the Company entered into a joint venture agreement with Virtual Psychedelics Incorporated to design, develop and commercialize the Krysalis Pod, a state-of-the-art media device that will deliver immersive virtual experiences without a headset. (the “JV”);
  • On April 29, 2021 we announced the filing of a PCT application entitled “Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury”;
  • On May 4, 2021 we announced the acquisition of the Vitamind line of functional mushroom wellness products; and
  • On May 19, 2021 we announced entering into a production and supply agreement with HAVN Life Sciences Inc.

As announced on March 8, 2021, the Company completed the divestiture of the Washington State cannabis asset to Ionic Brands Corp. (“Ionic“), strengthening our balance sheet with a cash payment to the Company of $1,750,000, and receipt of 100,406,701 Series E shares of Ionic and 4,000,000 Ionic warrants.

Executive Team, Advisors and Industry Relationships:

In 2021, in addition to myself as CEO, we added Michael Petter, an accomplished businessman to our board of directors. We also assembled an accomplished Scientific Advisory Board (“SAB”), led by our CSO, Maghsoud Dariani, including Dr. Mark Geyer, Dr. Charles Grob, Dr. Benjamin Kelmendi, Dr. Michael Hoffer and Dr. Skip Rizzo, all regarded as leaders and innovators in their respective psychedelic and medical communities. We also leveraged our advisor network and partnered with the NFL Alumni Association and the World Boxing Association to investigate and develop plans for monitoring, mitigating and managing the consequences of mTBI and PTSD.

Looking Ahead: on-going corporate initiatives

The Company intends to leverage its 2021 accomplishments achieved to-date. Key milestones we anticipate working towards include the following items. The Company plans on completing these items by the end of calendar 2022, barring any unforeseen delays.

Clinical and Scientific Development and Regulatory

  • Announce the results of the University of Miami Pre Clinical Study of the treatment of mTBI and PTSD
  • Submit Pre Investigational New Drug (“IND“) meeting request to FDA
  • Announce contract research organization (“CRO“) partner, finalize study protocol, select sites for first-in-man study with our combination therapeutics
  • Finalize agreement with a cGMP manufacturing partner for clinical trial and commercial supplies of psilocybin and NAC (N-Acetylcysteine)
  • Initiate the first human study with Lobe’s patent pending combination therapeutics of psilocybin and NAC (N-Acetylcysteine)
  • Update on cGMP psilocybin production timing and availability
  • File IND with FDA
  • Update clinical trial enrolment progress
  • Update IND plans based on feedback from FDA
  • Finalize specifications for and design plan for nasal mist delivery device

Collaborations and Partnerships

  • Update on Krysalis Pod design team and progress
  • Launch the first products in the Vitamind product portfolio, subject to regulatory approval
  • Update on Krysalis Pod design and tech stack development
  • Expand Vitamind product offerings and launch in USA, subject to regulatory approval

Investment Conference Schedule:

The Company will be sharing its vision and plans with investors as we attend several leading investment conferences and trade conventions including:

  • HC Wainwright 23rd Global Investment Conference, September 13-15, 2021
  • Maxim Group, Advances in Mental Health – Psychedelics and Non-Psychedelics Conference, September 22, 2021
  • Benzinga Healthcare Small Cap Conference, September 29, 2021
  • MoneyShow Virtual Expo, October 5-7, 2021
  • BioFuture 2021, October 5-7, 2021
  • LD Micro Main Event, October 12-14, 2021
  • Q4 Investor Summit Virtual Conference, November 16-17, 2021
  • JP Morgan Healthcare Conference, January 10-13, 2022

In summary, we believe the balance of 2021 and 2022 will bring exciting developments as we build on the foundation of our accomplishments. We are committed to creating effective therapies and treatments to better the lives of millions of people. We believe we have built a solid foundation and strategy that incorporates strong partnerships with recognized industry leaders, a world-class Scientific Advisory Board, a growing intellectual property portfolio, along with multiple products and devices under development.

Thank you for your continued commitment and support as we continue to execute our strategy to position the Company for long-term growth and success.

Philip Young
CEO and Director

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements made by our Chief Executive Officer and regarding the future plans and objectives of the Company; progression with nasal mist device engineering and commercialization; the pursuit of M&A initiatives, and the expected benefits to be derived from previous M&A initiatives; the development of effective delivery methods and commercialization potential of the nasal mist device, research and development using NAC and psilocybin and growth of the business; the Company’s expected attendance at various industry conferences; the timing of and results from the University of Miami pre-clinical study; expected timing to submit a pre IND meeting request to the FDA (and statements regarding FDA approvals generally); expected announcement and timing of a CRO partner, finalizing study protocol, and statements regarding a first-in-man study with our combination therapeutics; statements regarding expected development of the Krysalis Pod; anticipated timing and announcement of initiation of the first human study with Lobe’s patent pending combination therapeutics of psilocybin and NAC (N-Acetylcysteine); expected timing and occurrence of the launch of products in the Vitamind product portfolio, expansion of the Vitamind product line and receipt of regulatory approvals required for product launches; expected statements and timing regarding cGMP psilocybin production and availability; and the expected timing for the launch of new products and revenue-generating activities and expected completion of milestones by the end of calendar 2022, are all forward looking statements that involve risks and uncertainties. Forward-looking statements, by their very nature, require management to make assumptions and are subject to inherent risks and uncertainties, and while management of the Company believes the forward-looking statements contained herein have a reasonable basis, the possibility exists that our predictions, forecasts, projections, expectations or conclusions will not prove to be accurate. Material assumptions that underlie the forward-looking statements included in this news release include, without limitation, assumptions regarding: the outcomes of scientific studies showing the efficacy of psychedelic therapies on mTBI and PTSD, increasing acceptance in the medical community and among consumers for psychedelic therapies as an effective treatment modality; the Company having access to sufficient capital needed to support its various milestone objectives, expected synergies from M&A transactions and the timing of various milestone objectives, regulatory approvals and our ability to capitalize on business opportunities and develop revenue-generating activities; and the impact of COVID-19 on our business plans. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. As a result of the inherent uncertainty of forward-looking statements, there can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements, whether as a result of known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Important risks and uncertainties that could cause actual results to differ materially from the Company’s expectations include without limitation risks relating to: that we may not have the capital needed or will not be able to raise sufficient capital to support our business activities or achieve our anticipated milestones; delays or stoppages in the Company’s business activities resulting from the COVID-19 pandemic; adverse or unexpected findings in scientific research; adverse changes to the regulatory environment in which we operate; regulatory delays or the failure to obtain required regulatory approvals; failure to capitalize on business opportunities and develop revenue-generating activities; contract counterparty risks; key personnel risk; business integration risks; risks inherent to equity and debt markets and their effects on our share price, and such other risks as may be detailed from time to time in the filings made by the Company pursuant to securities regulations, as well as other risks that may presently be unknown to us or which we consider to be immaterial at the time such forward-looking statements are made. As a result of these risks and uncertainties, the Company cannot guarantee that any forward-looking statement will materialize as expected, and the reader is therefore cautioned not to place undue reliance on any forward-looking statements contained in this news release. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement, are made only as of the date of this news release and the Company does not intend to update any of the forward-looking statements contained in this news release except as expressly required by applicable securities laws.

Posted on

Lobe Sciences to Present At H.C. Wainwright 23rd Annual Global Investment Conference

Lobe Sciences to Present At H.C. Wainwright 23rd Annual Global Investment Conference

Vancouver, British Columbia–(Newsfile Corp. – September 10, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright 23rd Annual Global Investor Conference taking place Sept. 13-15, 2021.

The presentation will be available on demand through the H.C. Wainwright conference portal, beginning at 7:00 a.m. ET on Monday, Sept. 13, 2021.

Registration for the event is accessible via www.hcwevents.com/annualconference.

The Company will also participate in one-on-one meetings during the conference.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company’s corporate goals and objectives; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.